News

ALLO-329 gets FDA fast track designation for diffuse scleroderma

The U.S. Food and Drug Administration (FDA) has granted fast track designation to the cell therapy ALLO-329 to treat active refractory (resistant to treatment) diffuse scleroderma, also known as diffuse systemic sclerosis (SSc). The FDA also gave ALLO-329 fast track designation as a potential treatment for two other inflammatory…

Poor sleep in scleroderma linked to inadequate sleep hygiene: Study

People with systemic sclerosis (SSc) face significantly worse sleep quality than those with rheumatoid arthritis (RA) and healthy people, a study reports. Poor sleep hygiene and clinical factors, including gastroesophageal reflux disease, that is, acid reflux, and depression-like symptoms, were key contributors. These findings highlight how “enhancing sleep hygiene…

Immunosuppressants may help treat scleroderma with heart involvement

Immunosuppressive medications may help to reduce inflammation in the heart and the overall burden of primary heart involvement that is associated with systemic sclerosis (SSc), a retrospective study suggests. Larger studies are needed to confirm these findings, its researchers stated. The study, “Immunosuppressive therapy to treat newly diagnosed…